{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:54:24Z","timestamp":1773251664248,"version":"3.50.1"},"reference-count":17,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) and white blood cell (WBC) counts in ALC patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Department of hepatology, general hospital<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS AND METHODS:<\/jats:title>\n            <jats:p>Patients with ALC who had thrombocytopenia and\/or leukopenia were enrolled between 2022 and 2023 and were divided into two groups based on their treatment: the leucogen group (20 mg, three times per day) and the non-leucogen group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOME MEASURES:<\/jats:title>\n            <jats:p>The primary endpoint was an increase in PLT or WBC of \u22655% from baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SAMPLE SIZE:<\/jats:title>\n            <jats:p>413 patients (320 patients in the final analysis)<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>\n              In this retrospective study, 320 patients were analyzed post-propensity score matching: 160 patients each in the leucogen and non-leucogen groups. Following 3 months of treatment, the leucogen group experienced a median increase in PLT levels of 1.0\u00d710\n              <jats:sup>9<\/jats:sup>\n              \/L versus a decrease of 3.0\u00d710\n              <jats:sup>9<\/jats:sup>\n              \/L in the non-leucogen group (\n              <jats:italic>P<\/jats:italic>\n              =.003), and a median increase in WBC counts of 0.1\u00d710\n              <jats:sup>9<\/jats:sup>\n              \/L compared to a decrease of 0.1\u00d710\n              <jats:sup>9<\/jats:sup>\n              \/L (\n              <jats:italic>P<\/jats:italic>\n              =.006). The changes in ALT, AST, and TBIL levels were not significantly different between groups. A higher proportion of patients in the leucogen group experienced increases in both PLT (46.9% vs. 32.5%,\n              <jats:italic>P<\/jats:italic>\n              =.012) and WBC counts (50.0% vs. 36.2%,\n              <jats:italic>P<\/jats:italic>\n              =.018), and 28.1% of patients in the leucogen group had increases in both parameters, compared to 15.6% in the non-leucogen group (\n              <jats:italic>P<\/jats:italic>\n              =.01). The leucogen group also demonstrated greater increases in PLT (OR 1.833;\n              <jats:italic>P<\/jats:italic>\n              =.009) and WBC counts (OR 1.759;\n              <jats:italic>P<\/jats:italic>\n              =.013) compared to the non-leucogen group. The safety profile of leucogen was favorable, with no significant adverse events reported. Leucogen was particularly beneficial for patients younger than 60 years and those with lower baseline ALT and AST levels, showing significant improvements in both PLT and WBC counts in these subgroups.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Leucogen effectively increased PLT and WBC counts in patients with ALC, showing a favorable safety profile.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>LIMITATIONS:<\/jats:title>\n            <jats:p>Retrospective study<\/jats:p>\n          <\/jats:sec>","DOI":"10.5144\/0256-4947.2025.9","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T03:58:36Z","timestamp":1739246316000},"page":"9-17","source":"Crossref","is-referenced-by-count":4,"title":["The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia"],"prefix":"10.5144","volume":"45","author":[{"given":"Min","family":"Su","sequence":"first","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwen","family":"He","sequence":"additional","affiliation":[{"name":"From Peking University 302 Clinical Medical School, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"From Hospital of North China Electric Power University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu-Cai","family":"Yang","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Guo","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming","family":"Fu","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyao","family":"Li","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"},{"name":"From Peking University 302 Clinical Medical School, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Ji","sequence":"additional","affiliation":[{"name":"From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;"},{"name":"From Peking University 302 Clinical Medical School, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2876-4016","authenticated-orcid":true,"given":"Hong-Yan","family":"Chen","sequence":"additional","affiliation":[{"name":"From Hospital of North China Electric Power University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3134","reference":[{"issue":"1","key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","article-title":"Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors","volume":"20","author":"Huang DQ","year":"2023","unstructured":"Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):37\u201349. PMCID: PMC9579565","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani SK","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019 Jan;70(1):151\u2013171. PMID: 30266282","journal-title":"J Hepatol"},{"issue":"10258","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204\u20131222. PMCID: PMC7567026","journal-title":"Lancet"},{"issue":"07","key":"e_1_3_3_5_2","first-page":"498","article-title":"Expert consensus for diagnosis and treatment of thrombocytopenia in China","volume":"59","author":"Chinese Society of Internal Medicine, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Internal Medicine, Chinese Medical Association, Wang J, Zhang F, Liu X, Tang C, Chen L, Han Y. Expert consensus for diagnosis and treatment of thrombocytopenia in China. Chin J Intern Med. 2020 Jul 1;59(07):498\u2013510.","journal-title":"Chin J Intern Med"},{"issue":"6","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic M","year":"2017","unstructured":"Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017 Jun;37(6):778\u2013793. PMID: 27860293","journal-title":"Liver Int"},{"issue":"3","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.seminhematol.2013.06.010","article-title":"Evaluation and management of patients with isolated neutropenia","volume":"50","author":"Newburger PE","year":"2013","unstructured":"Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013 Jul;50(3):198\u2013206. PMCID: PMC3748385","journal-title":"Semin Hematol"},{"issue":"10","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1155\/2014\/532191","article-title":"Management of thrombocytopenia in advanced liver disease","volume":"28","author":"Gangireddy VGR","year":"2014","unstructured":"Gangireddy VGR, Kanneganti PC, Sridhar S, Talla S, Coleman T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014 Nov;28(10):558\u2013564. PMCID: PMC4234356","journal-title":"Can J Gastroenterol Hepatol"},{"key":"e_1_3_3_9_2","first-page":"39","article-title":"The pathophysiology of thrombocytopenia in chronic liver disease","volume":"8","author":"Mitchell O","year":"2016","unstructured":"Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39\u201350. PMCID: PMC4847598","journal-title":"Hepat Med"},{"issue":"10","key":"e_1_3_3_10_2","first-page":"2307","article-title":"Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia","volume":"39","author":"National Clinical Research Center for Infectious Diseases, Society of Hepatology, Beijing Medical Association, Translational Medicine Branch, Chinese Association of Gerontology and Geriatrics","year":"2023","unstructured":"National Clinical Research Center for Infectious Diseases, Society of Hepatology, Beijing Medical Association, Translational Medicine Branch, Chinese Association of Gerontology and Geriatrics. Chinese expert consensus on clinical management of hepatopathy-related thrombocytopenia. J Clin Hepatol. 2023;39(10):2307\u20132320.","journal-title":"J Clin Hepatol"},{"issue":"6","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MCG.0000000000001338","article-title":"Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure","volume":"54","author":"Saab S","year":"2020","unstructured":"Saab S, Bernstein D, Hassanein T, Kugelmas M, Kwo P. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure. J Clin Gastroenterol. 2020 Jul;54(6):503\u2013511. PMID: 32195771","journal-title":"J Clin Gastroenterol"},{"issue":"19","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.7314\/APJCP.2014.15.19.8495","article-title":"Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia","volume":"15","author":"Huang XE","year":"2014","unstructured":"Huang XE, Cao J, Qian ZY, Xu X, Shi L, Wu XY, Liu J, Wang L. Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev. 2014;15(19):8495\u20138497. PMID: 25339053","journal-title":"Asian Pac J Cancer Prev"},{"issue":"16","key":"e_1_3_3_13_2","first-page":"131","article-title":"Efficacy of High-dose Leucogen on Bone Marrow Suppression Induced by Intensity-modulated Conformal Radiotherapy for Pelvic Tumors","volume":"34","author":"Zhang Y sheng","year":"2021","unstructured":"Zhang Y sheng, Tang W bin. Efficacy of High-dose Leucogen on Bone Marrow Suppression Induced by Intensity-modulated Conformal Radiotherapy for Pelvic Tumors. Journal of Medical Information. 2021;34(16):131\u2013133.","journal-title":"Journal of Medical Information"},{"issue":"4","key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/1751-2980.12687","article-title":"Guidelines of prevention and treatment for alcoholic liver disease (2018, China)","volume":"20","author":"Li YM","year":"2019","unstructured":"Li YM, Fan JG, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease (2018, China). J Dig Dis. 2019 Apr;20(4):174\u2013180. PMID: 30450822","journal-title":"J Dig Dis"},{"issue":"30","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3748\/wjg.v28.i30.4061","article-title":"Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures","volume":"28","author":"Gallo P","year":"2022","unstructured":"Gallo P, Terracciani F, Di Pasquale G, Esposito M, Picardi A, Vespasiani-Gentilucci U. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures. World J Gastroenterol. 2022 Aug 14;28(30):4061\u20134074. PMCID: PMC9403422","journal-title":"World J Gastroenterol"},{"issue":"2","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.21.00608","article-title":"Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial","volume":"40","author":"Li QJ","year":"2022","unstructured":"Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2022 Jan 10;40(2):150\u2013160. PMID: 34648352","journal-title":"J Clin Oncol"},{"issue":"33","key":"e_1_3_3_17_2","first-page":"2579","article-title":"Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition)","volume":"103","author":"Society of Chemotherapy, China Anti-Cancer Association, Committee of Neoplastic Supportive-Care, China Anti-Cancer Association","year":"2023","unstructured":"Society of Chemotherapy, China Anti-Cancer Association, Committee of Neoplastic Supportive-Care, China Anti-Cancer Association, Feng Jifeng, Shi Yanxia, Shen Bo. Consensus on the clinical diagnosis, treatment and prevention of cancer treatment-induced thrombocytopenia in China (2023 edition). Natl Med J China. 2023 Sep;103(33):2579\u20132590.","journal-title":"Natl Med J China"},{"issue":"24","key":"e_1_3_3_18_2","first-page":"4204","article-title":"Clinical Efficacy of Recombinant Human Granulocyte Colony-Stimulating Factor Injection Combined with Leucogen in Treating Granulocytopenia After Chemotherapy for Malignant Tumors","volume":"36","author":"Liu Gang","year":"2023","unstructured":"Liu Gang. Clinical Efficacy of Recombinant Human Granulocyte Colony-Stimulating Factor Injection Combined with Leucogen in Treating Granulocytopenia After Chemotherapy for Malignant Tumors. J Med Theor & Prac. 2023 Dec;36(24):4204\u20134206.","journal-title":"J Med Theor & Prac"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T02:28:41Z","timestamp":1739932121000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2025.9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.5144\/0256-4947.2025.9"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2025.9","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}